PhotoDetection Systems (PDS) has received clearance from the FDA for its NeuroPET scanner, which was designed to serve the clinical and research needs of the molecular neuroimaging community.
NeuroPET's patented wavelength-shifting fiber technology enables high-sensitivity and spatial resolution, according to the Boxboro, Mass.-based company. It said the modality's compact/portable design requires no site preparation and uses very low doses of 18F and 11C tracers to image metabolism, amyloid, and dopaminergic binding in neurological diseases. The tracers are known to be helpful in imaging diseases such as Alzheimer's, Parkinson's, neuro-oncology and neuro-psychiatric disorders.
PhotoDetection Systems will be exhibiting at two upcoming conferences: the Society of Nuclear Medicine's (SNM) annual meeting in Toronto in June and the International Conference on Alzheimer's Disease (ICAD) in Vienna, Austria, in July.